For instance, TYRP1-directed CAR T cells effectively controlled tumor growth in xenograft models [38], and CSPG4-targeted CAR T cells demonstrated potent cytotoxicity and feasibility for clinical-scale mRNA-based manufacturing [39]. This evidence concerns the gene CSPG4 and neoplasm.